Table 1.
Baseline characteristics of transplant recipients by era in Australia and New Zealand
| Characteristics | Transplant Era, n (%) | |||
|---|---|---|---|---|
| 1980–1989 (n=3964) | 1990–1999 (n=4728) | 2000–2009 (n=6214) | 2010–2018 (n=8304) | |
| Age at transplant, in years (n=23,210) | ||||
| <18 | 307 (8) | 319 (7) | 351 (6) | 404 (5) |
| 18–34 | 1150 (29) | 1190 (25) | 1157 (19) | 1108 (13) |
| 35–49 | 1321 (33) | 1528 (32) | 1958 (32) | 2058 (25) |
| 50–65 | 1137 (29) | 1503 (32) | 2292 (37) | 3480 (42) |
| >65 | 49 (1) | 188 (4) | 456 (7) | 1254 (15) |
| Sex (n=23,210) | ||||
| Female | 1673 (42) | 1919 (41) | 2354 (38) | 2983 (36) |
| Male | 2291 (58) | 2809 (59) | 3860 (62) | 5321 (64) |
| Ethnicity (n=23,210) | ||||
| White | 3512 (89) | 3957 (84) | 5095 (82) | 5840 (70) |
| Indigenousa | 98 (2) | 157 (3) | 195 (3) | 273 (3) |
| Asian | 159 (4) | 328 (7) | 571 (9) | 1063 (13) |
| Other | 195 (5) | 285 (6) | 352 (6) | 908 (11) |
| Not reported | 0 (0) | 1 (0) | 1 (0) | 220 (3) |
| Time since first RRT (n=23,210) | ||||
| 0–1 yr | 1775 (45) | 1668 (35) | 1988 (32) | 2592 (31) |
| 1–3 yr | 1645 (42) | 1883 (40) | 2122 (34) | 2737 (33) |
| >3 yr | 544 (14) | 1177 (25) | 2104 (34) | 2975 (36) |
| Primary renal disease (n=23,210) | ||||
| GN | 1650 (42) | 2303 (49) | 2910 (47) | 3166 (38) |
| Renovascular | 152 (4) | 166 (4) | 276 (4) | 593 (7) |
| Diabetes | 239 (6) | 329 (7) | 518 (8) | 1203 (14) |
| Other | 1699 (43) | 1748 (37) | 2262 (36) | 2813 (34) |
| Uncertain | 224 (6) | 182 (4) | 248 (4) | 379 (5) |
| Not reported | 0 (0) | 0 (0) | 0 (0) | 150 (2) |
| Dialysis modality before transplant (n=23,210) | ||||
| Pre-emptive transplant | 90 (2) | 245 (5) | 807 (13) | 1084 (13) |
| HD | 2844 (72) | 3105 (66) | 3924 (63) | 4784 (58) |
| PD | 1030 (26) | 1378 (29) | 1483 (24) | 2436 (29) |
| Diabetes as comorbidity (n=21,483) | 261 (10) | 437 (10) | 743 (12) | 1752 (21) |
| Chronic lung disease (n=21,020) | 54 (2) | 170 (4) | 365 (6) | 672 (8) |
| CV disease (n=21,116) | 163 (7) | 522 (12) | 1193 (19) | 2037 (25) |
| Non–skin cancer diagnosis before transplant (n=23,210) | 60 (2) | 154 (3) | 264 (4) | 538 (6) |
| Number of HLA mismatches (n=22,763) | ||||
| 0 | 176 (5) | 275 (6) | 402 (6) | 322 (4) |
| 1–2 | 1488 (40) | 1912 (40) | 1867 (30) | 2069 (25) |
| 3–4 | 1786 (48) | 1919 (41) | 2285 (37) | 2813 (35) |
| 5–6 | 269 (7) | 610 (13) | 1637 (26) | 2933 (36) |
| Donor type/ischemia time (n=23,210) | ||||
| LD | 471 (12) | 1197 (25) | 2779 (45) | 2650 (32) |
| DD, <12 h | 83 (2) | 547 (12) | 1018 (16) | 2963 (36) |
| DD, 12–18 h | 244 (6) | 1499 (32) | 1670 (27) | 1824 (22) |
| DD, ≥18 h | 1284 (32) | 1385 (29) | 699 (11) | 592 (7) |
| Unknown | 1882 (48) | 100 (2) | 48 (1) | 275 (3) |
| CNI at transplant (n=23,058) | 2095 (54) | 4544 (96) | 6006 (97) | 7936 (96) |
| Tacrolimus | 0 (0) | 82 (2) | 2397 (39) | 6904 (84) |
| Cyclosporin | 2095 (54) | 4463 (94) | 3609 (58) | 1041 (13) |
| Antimetabolite at transplant (n=23,058) | 2849 (74) | 4321 (91) | 5864 (94) | 7943 (96) |
| Mycophenolate | 0 (0) | 945 (20) | 5721 (92) | 7919 (96) |
| Azathioprine | 2849 (74) | 3376 (71) | 144 (2) | 29 (0) |
| Prednisolone at transplant (n=23,058) | 3015 (78) | 4257 (90) | 6036 (97) | 7989 (97) |
| mTOR at transplant (n=23,058) | 0 (0) | 224 (5) | 278 (4) | 54 (1) |
| Anti-CD25 Rx (basiliximab or daclizumab) | 1 (0) | 46 (1) | 3430 (55) | 7445 (90) |
| T cell depletion (muromonab-CD3, antithymocyte globulin agents, or alemtuzumab) | 371 (9) | 312 (7) | 209 (3) | 342 (4) |
| BMI at transplant (n=17,621)b | ||||
| Underweight (<18.5 kg/m2) | 67 (8) | 138 (4) | 192 (3) | 187 (2) |
| Normal (18.5 to <25 kg/m2) | 551 (62) | 1783 (52) | 2446 (42) | 2464 (33) |
| Overweight (25 to <30 kg/m2) | 222 (25) | 1066 (31) | 2101 (36) | 2721 (36) |
| Obese (≥30 kg/m2) | 48 (5) | 446 (13) | 1112 (19) | 2077 (28) |
| Smoking status at RRT entry (n=19,615) | ||||
| Current | 210 (16) | 487 (12) | 680 (11) | 713 (9) |
| Former | 263 (20) | 1122 (28) | 1849 (30) | 2749 (34) |
| Never | 866 (65) | 2348 (59) | 3678 (59) | 4650 (57) |
| eGFR category 1 mo after transplant (n=21,283) | ||||
| <15 ml/min | 325 (10) | 212 (5) | 158 (3) | 270 (4) |
| 15 to <30 ml/min | 561 (18) | 495 (11) | 594 (10) | 875 (11) |
| 30 to <60 ml/min | 1576 (49) | 2503 (57) | 3270 (55) | 3973 (51) |
| 60 to <90 ml/min | 564 (18) | 957 (22) | 1563 (26) | 2090 (27) |
| ≥90 ml/min | 162 (5) | 224 (5) | 343 (6) | 568 (7) |
HD, hemodialysis; PD, peritoneal dialysis; CV, cardiovascular; LD, living donor; DD, deceased donor; CNI, calcineurin inhibitor; mTOR, mammalian target of rapamycin; Rx, prescription; BMI, body mass index.
a
Indigenous: Aboriginal and Torres Strait Islanders.
b
BMI for adult patients (≥18 yr old) only.